E
NVCR icon

Ergoteles’s NovoCure NVCR Stock Holding History

Ergoteles’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,798
Closed -$1.28M – 1750
2022
Q3 		$1.28M Buy
+16,798
New +$1.31M 0.04% 401
2021
Q3 		– Sell
-23,548
Closed -$5.22M – 1543
2021
Q2 		$5.22M Buy
+23,548
New +$4.58M 0.12% 221
2021
Q1 		– Sell
-30,400
Closed -$5.26M – 983
2020
Q4 		$5.26M Buy
30,400
+20,475
+206% +$2.8M 0.17% 131
2020
Q3 		$1.1M Buy
+9,925
New +$794K 0.15% 133

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's NVCR Position: Q4 2022 in Review

Ergoteles sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 16,798 shares — an estimated $1.28M sold.

Ergoteles first reported a position in NVCR in Q3 2020 and held it in 4 quarters. The position peaked at $5.26M in Q4 2020. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Ergoteles reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 16,798 NovoCure shares in Q4 2022, an estimated $1.28M.
  • Ergoteles first reported a position in NovoCure in Q3 2020 and held it in 4 quarters.
  • Ergoteles's NovoCure position peaked at $5.26M in Q4 2020.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.